- Home
- MGEE vs CDNA Comparison
MGEE vs CDNA Comparison
Compare MGEE & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGEE | CDNA |
|---|---|---|
| Founded | 1855 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | 2001 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MGEE | CDNA |
|---|---|---|
| Price | $73.63 | $68.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $76.83 | $64.17 |
| AVG Volume (30 Days) | 144.5K | ★ 1.3M |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | ★ 11.71 | N/A |
| EPS | 1.32 | ★ 2.13 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $7.30 | $30.36 |
| Revenue Next Year | $5.22 | $6.23 |
| P/E Ratio | $55.85 | ★ $32.46 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $68.01 | $14.23 |
| 52 Week High | $86.81 | $72.71 |
Technical Indicators
Market Signals| Indicator | MGEE | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 61.51 |
| Support Level | $72.44 | $17.30 |
| Resistance Level | $81.83 | $72.51 |
| Average True Range (ATR) | 1.30 | 3.95 |
| MACD | 0.60 | -0.16 |
| Stochastic Oscillator | 78.40 | 64.67 |
Price Performance
Historical ComparisonAbout MGEE MGE Energy Inc
MGE Energy provides electric service to 170,000 customers and natural gas service to 180,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.